SCHEMBL1963479

SCHEMBL1963479

CCOC(=O)c1cccc(Nc2ccc(OC)cc2OC)c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.54
TP53 P04637 4/20 0.52
MAPT P10636 4/20 0.52
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
TOP1 P11387 1/20 0.49
KDM4E B2RXH2 1/20 0.49
APAF1 O14727 1/20 0.49
RECQL P46063 1/20 0.49
CASP6 P55212 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
MCL1 Q07820 1/20 0.49
CASP8 Q14790 1/20 0.49
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964931 0.92 CDC25B (0.50) CDC25BTP53MAPTAKR1C3AKR1C2
SCHEMBL1964094 0.91 CDC25B (0.55) CDC25BTP53MAPTAKR1C3AKR1C2
SCHEMBL1964675 0.87 CDC25B (0.46) CDC25BTP53MAPTKDM4EAPAF1
SCHEMBL1963248 0.87 CDC25B (0.44) CDC25BTP53MAPTAKR1C3AKR1C2
SCHEMBL1962918 0.87 CDC25B (0.59) CDC25BMAPTAKR1C3AKR1C2KDM4E
SCHEMBL1961624 0.87 AKR1C3 (0.62) CDC25BMAPTAKR1C3AKR1C2TOP1
SCHEMBL1961738 0.86 CDC25B (0.45) CDC25BTP53MAPTKDM4EAPAF1
SCHEMBL1963639 0.84 CDC25B (0.49) CDC25BTP53MAPTAKR1C3AKR1C2
SCHEMBL1962517 0.84 KMT2A (0.46) CDC25BKDM4EALDH1A1TSHRGAA
SCHEMBL1961347 0.84 AKR1C3 (0.57) CDC25BTP53MAPTAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919892-B1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2013-08-14 EP disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
EP-1919892-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-05-14 EP disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SI, CYP3A5, CYP2D6 CDC25B 420/4885TP53 245/4885MAPT 553/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 CDC25B 420/4885TP53 245/4885MAPT 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.